3) Holding Policy Makers Accountable for Policy Claims

    • The controversial practice of importing drugs not only from Canada but nations around the world, many with lax regulatory and safety oversight
    • The unproven policy of setting drug prices through a Prescription Drug Affordability board (PDAB) which could compromise access to life saving medicines
    • Transparency rules and regulations that disproportionately affect one player in the health care system over others
    • Insufficient regulation of low-value middle actors such as Pharmacy Benefit Managers (PBMs) that add enormous cost to the drug supply chain